Acute myeloid leukemias (AMLs) are characterized by a variety of genetic defects that contribute to the failure of these cells to undergo differentiation to mature granulocytes or monocytes/ macrophages. A primary consequence of this failure to differentiate is the accumulation of proliferative blasts in the bone marrow and peripheral blood. In the case of one subtype of AML, acute promyelocytic leukemia (APL; FAB M3), differentiation can be induced by all-trans retinoic acid (ATRA), a treatment that is curative for many acute promyelocytic leukemia patients. 1, 2 However, ATRA has not proven to be effective in the treatment of other subtypes of AML, underscoring the need to identify new compounds that can either induce differentiation as monotherapies or enhance the efficacy of ATRA therapy. Here we report that the tyrosine kinase inhibitor gefitinib markedly enhances ATRA-induced differentiation in myeloid cell lines.
We and others have shown that ATRA-induced monocytic and granulocytic differentiation is dependent on activation of serine/threonine kinases in the mitogen-activated protein kinase kinase/extracellular-regulated kinase (MEK/ERK) signaling pathway. 3 In addition, we have reported that pharmacologic inhibition of Src family kinases results in enhancement of ATRA-induced myeloid differentiation. 4 These results indicate that tyrosine kinases in the Src family kinase family act as negative regulators of ATRA-induced differentiation. Recently, Stegmaier et al. 5 have shown that the pharmacologic inhibitor gefitinib stimulates differentiation of the myeloid cell lines HL-60, Kasumi-1 and U937. Gefitinib is a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase and has been approved by the Food and Drug Administration for treatment of non-small cell lung cancer. 6 Interestingly, the epidermal growth factor receptor does not appear to be expressed in AML cells, indicating that the differentiationinducing effects of gefitinib are likely due to inhibition of, as yet unidentified, cellular tyrosine kinases. 5 The inhibition of a variety of cellular kinases by low micromolar concentrations of gefitinib has been reported. 7 Despite an unclear mechanism of action, we sought to determine whether gefinitib might act in synergy with low-dose ATRA to stimulate myeloid differentiation.
As shown in Figure 1 , gefitinib (10 mM; kindly provided by AstraZeneca, London, UK) dramatically enhanced ATRAinduced differentiation of HL-60 cells. In Figure 1a , induction of differentiation was assessed using flow cytometric analysis of the myeloid marker protein CD11b. Treatment of HL-60 cells for 3 days with 2 mM of ATRA alone resulted in 19.2% CD11b-positive cells, while only 1.9% of cells treated with Letters to the Editor gefitinib (10 mM) alone were CD11b-positive. By contrast, cells treated simultaneously with ATRA and gefitinib scored as 65.2% CD11b-positive. Similar results were obtained in three independent experiments. The ability of gefitinib to enhance ATRA-induced HL-60 cell differentiation was confirmed using assays that scored differentiation on the basis of nitroblue tetrazolium staining (Figure 1b ) or cellular morphology (Figure 1c) . Strikingly, enhancement of ATRA-induced differentiation was observed even when gefitinib was added as late as 24 h after initiation of ATRA treatment (data not shown), suggesting that inhibition of later or prolonged kinase signaling is important.
The ability of gefitinib to enhance ATRA-induced differentiation was not restricted to HL-60 cells. Treatment of NB-4 cells with the suboptimal dose of 0.01 mM ATRA resulted in 6.5% CD11b-positive cells after 3 days, while treatment with gefitinib alone (10 mM) generated only 2.8% CD11b-positive cells (Figure 2a ). The combination of ATRA and gefitinib, however, yielded 41.7% CD11b positivity. Similarly, the combination of ATRA and gefitinib resulted in enhanced induction of U937 cell differentiation, as assessed by CD11b expression analysis (Figure 2b) .
In prior studies, activation of the MEK/ERK pathway has been shown to be important for ATRA-induced myeloid differentiation. To determine whether activation of this pathway is required for the enhanced differentiation observed with the combination of ATRA and gefitinib, HL-60 cells treated with the ATRA/gefitinib combination were simultaneously incubated with the MEK-1/-2 inhibitor U0126 (10 mM). Previous experiments have shown that 10 mM U0126 results in nearly complete inhibition of the MEK/ERK pathway in myeloid lineage cells. 8 As shown in Figure 3 , inhibition of the MEK/ERK pathway using U0126 resulted in abrogation of HL-60 cell differentiation by the ATRA/gefitinib combination. This suggests that the MEK/ERK pathway lies downstream of the signaling components impacted by either ATRA or gefitinib.
In conclusion, we have demonstrated that the tyrosine kinase inhibitor gefitinib markedly enhances ATRA-induced differentiation of myeloid cell lines. It remains to be determined whether gefitinib enhancement of ATRA-induced differentiation will be observed in vivo at clinically achievable doses. In addition, it remains unclear which cellular kinases are being targeted by gefitinib to elicit enhancement of ATRA action, although their elucidation may provide novel targets for therapeutic intervention in AML. In the meantime, application of Food and Drug Administration-approved gefitinib, or related inhibitors, should be considered as a means of enhancing ATRA sensitivity in AML. Figure 3 The MEK/ERK pathway is essential for gefitinib enhancement of ATRA-induced differentiation. HL-60 cells were left untreated or were treated for 72 h with ATRA alone (2 mM), U0126 alone (10 mM), ATRA plus gefitinib or ATRA plus gefitinib plus U0126. Numbers indicate the percent of cells staining positive for CD11b. ATRA, all-trans retinoic acid. The success of haematopoietic stem cell transplantation depends upon the pretransplant leukaemic burden. 1 In relapsed or refractory acute leukaemia and high-grade non-Hodgkin's lymphoma, the main aim is to decrease the leukaemic cell population to submicroscopic level so that consolidation with haematopoietic stem cell transplantation can be performed. In these heavily pretreated patients, there are issues of development of drug resistance and further risk of comorbidities from salvage chemotherapy. Thus for prolonged survival of such patients, a protocol that can induce disease remission to last long enough to perform haematopoietic stem cell transplantation and also prevent vital organ dysfunction is required.
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Topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) have been reported previously in children with relapsed or refractory leukaemia as institutional phase 2 non-randomized single-arm reinduction protocol. 2 In the study reported by Kolb and Steinherz, 2 28 children were treated with TVTG protocol, of which 13 (47%) achieved significant response with acceptable toxicities and 10 (36%) underwent haematopoietic stem cell transplantation. In view of these promising results in the children, we introduced TVTG regimen in adults who have been heavily pretreated for relapsed or refractory leukaemia and high-grade non-hodgkin's lymphoma. There is no report, to our knowledge in the literature, of TVTG being used in adults.
We report a single-institutional retrospective analysis of 11 consecutive patients treated with protocol comprising of TVTG from July 2004 to September 2006. All patients had relapsed and/or refractory leukaemia or lymphoma with Eastern Cooperative Oncology Group performance status of 0 and none of them had other therapeutic options according to our hospital treatment standards. From all the patients, written informed consent was obtained before initiation of therapy. TVTG treatment schedule is shown in Table 1 .
Patient characteristics are presented in Table 2 . Response was assessed by cytomorphological examination, minimal residual disease by flow cytometry and computed tomography after completion of chemotherapy.
In this analysis of 11 patients, nine were male and two were female. The median age at initial diagnosis was 33 years (range 16-49 years), and the median age when they were treated with TVTG was 34 years (range 16-54 years). Five patients had B-cell acute lymphoblastic leukaemia/lymphoma (ALL) (three common ALL, one each had pre-B-cell ALL and transformed B-cell ALL), three had T-cell ALL, one each had acute myeloid leukaemia , Burkitt's lymphoma and transformed chronic lymphocytic leukaemia. Three patients were primary refractory, six were refractory in first relapse, one was refractory in second relapse and one patient was treated with TVTG in second relapse.
Nine patients had an identified donor and in the remaining two, the donor search was initiated prior to starting of TVTG. All patients in this study received one cycle of TVTG where as in paediatric phase 2 trial by Kolb et al., 2 8 out of 13 responsive patients received more than one cycle.
All patients received gemcitabine on day 7 and at least two doses of vinorelbine on day 0 and day 7. Five patients received day 14 dose of vinorelbine at physician's discretion, depending upon the tolerability of the TVTG protocol. Only one patient received day 21 dose of vinorelbine.
In various phase 1 trials for refractory leukaemias, gemcitabine has been proven to be active either as a single agent or in combination. The role of gemcitabine in TVTG combination however is not very clear. Recent phase 2 trials of single agent gemcitabine in relapsed childhood leukaemia have not been effective and hence role of gemcitabine in TVTG protocol needs a careful assessment. 3, 4 Vinorelbine (vinca alkaloid)-based salvage regimens have been used for therapy-refractory aggressive leukaemias with objective responses. 5 Topotecan, which is a topoisomerase I inhibitor, has demonstrated activity in relapsed/refractory leukaemias. 6 It has shown efficacy when used in combination with agents like Day 7 gemcitabine was given only if liver transaminases were o5 Â upper limit of normal with a bilirubin less than 1.5 Â upper limit of normal.
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